The Gist: They think they can start wider human trials soon which would last 2 years then have a product in 3 to 4 years.
In this video, Drs Irina and Mike Conboy talk how TPE, therapeutic plasma exchange is already available as an FDA approved procedure and the plans to extend the usage to include more age related diseases. We also discuss the company that they have formed IMU
Our guests today are Drs. Irina and Michael Conboy of the Department of Bioengineering at the University of California Berkeley. their discovery of the rejuvenating effects of young blood through parabiosis in a seminal paper published in Nature in 2005 paved the way for a thriving field of rejuvenation biology. The Conboy lab currently focuses on broad rejuvenation of tissue maintenance and repair, stem cell niche engineering, elucidating the mechanisms underlying muscle stem cell aging, directed organogenesis, and making CRISPR a therapeutic reality.